Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Improving cardiovascular and renal outcomes in gout: what should we target?
Pascal Richette, Fernando Perez‐Ruiz, Michael Doherty, et al.
Nature Reviews Rheumatology (2014) Vol. 10, Iss. 11, pp. 654-661
Closed Access | Times Cited: 205

Showing 1-25 of 205 citing articles:

Gout: An old disease in new perspective – A review
Gaafar Ragab, Mohsen Elshahaly, Thomas Bardin
Journal of Advanced Research (2017) Vol. 8, Iss. 5, pp. 495-511
Open Access | Times Cited: 490
Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options
Thomas Bardin, Pascal Richette
BMC Medicine (2017) Vol. 15, Iss. 1
Open Access | Times Cited: 308
Physiology of Hyperuricemia and Urate-Lowering Treatments
Caroline Benn, Vivek Dua, Rachel Gurrell, et al.
Frontiers in Medicine (2018) Vol. 5
Open Access | Times Cited: 273
A Review of Uric Acid, Crystal Deposition Disease, and Gout
Fernando Perez‐Ruiz, Nicola Dalbeth, Thomas Bardin
Advances in Therapy (2014) Vol. 32, Iss. 1, pp. 31-41
Open Access | Times Cited: 225
Comorbidities in patients with gout prior to and following diagnosis: case-control study
Chang‐Fu Kuo, Matthew J. Grainge, Christian Mallen, et al.
Annals of the Rheumatic Diseases (2014) Vol. 75, Iss. 1, pp. 210-217
Open Access | Times Cited: 210
SGLT2 Inhibition in the Diabetic Kidney—From Mechanisms to Clinical Outcome
Erik J.M. van Bommel, Marcel H.A. Muskiet, Lennart Tonneijck, et al.
Clinical Journal of the American Society of Nephrology (2017) Vol. 12, Iss. 4, pp. 700-710
Open Access | Times Cited: 204
Lesinurad Combined With Allopurinol: A Randomized, Double‐Blind, Placebo‐Controlled Study in Gout Patients With an Inadequate Response to Standard‐of‐Care Allopurinol (a US‐Based Study)
Kenneth G. Saag, David Fitzpatrick, Jeff Kopicko, et al.
Arthritis & Rheumatology (2016) Vol. 69, Iss. 1, pp. 203-212
Open Access | Times Cited: 169
Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials
Markus Bredemeier, Lediane Moreira Lopes, Matheus Augusto Eisenreich, et al.
BMC Cardiovascular Disorders (2018) Vol. 18, Iss. 1
Open Access | Times Cited: 162
Gout: state of the art after a decade of developments
Tristan Pascart, Frédéric Lioté
Lara D. Veeken (2018)
Open Access | Times Cited: 159
Recent advances on uric acid transporters
Liuqing Xu, Yingfeng Shi, Shougang Zhuang, et al.
Oncotarget (2017) Vol. 8, Iss. 59, pp. 100852-100862
Open Access | Times Cited: 155
Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial
Nicola Dalbeth, Graeme Jones, Robert Terkeltaub, et al.
Arthritis & Rheumatology (2017) Vol. 69, Iss. 9, pp. 1903-1913
Open Access | Times Cited: 142
Uric acid and incident dementia over 12 years of follow-up: a population-based cohort study
Augustin Latourte, Aïcha Soumaré, Thomas Bardin, et al.
Annals of the Rheumatic Diseases (2017) Vol. 77, Iss. 3, pp. 328-335
Open Access | Times Cited: 125
Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in Clinical Situations
Hiroshi Miyata, Tappei Takada, Yu Toyoda, et al.
Frontiers in Pharmacology (2016) Vol. 7
Open Access | Times Cited: 123
Chinese Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Hyperuricemia and Related Diseases
Multidisciplinary Expert Task Force on Hyperuricemia and Related Diseases
Chinese Medical Journal (2017) Vol. 130, Iss. 20, pp. 2473-2488
Open Access | Times Cited: 107
Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study
Anne‐Kathrin Tausche, Rieke Alten, Nicola Dalbeth, et al.
Lara D. Veeken (2017) Vol. 56, Iss. 12, pp. 2170-2178
Open Access | Times Cited: 106
Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care
Hyon K. Choi, Natalie McCormick, Chio Yokose
Nature Reviews Rheumatology (2021) Vol. 18, Iss. 2, pp. 97-111
Closed Access | Times Cited: 86
Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial
Atsushi Tanaka, Isao Taguchi, Hiroki Teragawa, et al.
PLoS Medicine (2020) Vol. 17, Iss. 4, pp. e1003095-e1003095
Open Access | Times Cited: 74
Prevalence of Gout in the Adult Population of France
Thomas Bardin, S. Bouée, Pierre Clerson, et al.
Arthritis Care & Research (2015) Vol. 68, Iss. 2, pp. 261-266
Closed Access | Times Cited: 89
Hyperuricemia starts at 360 micromoles (6mg/dL)
Thomas Bardin
Joint Bone Spine (2015) Vol. 82, Iss. 3, pp. 141-143
Closed Access | Times Cited: 77
Investigational drugs for hyperuricemia, an update on recent developments
Tristan Pascart, Pascal Richette
Expert Opinion on Investigational Drugs (2018) Vol. 27, Iss. 5, pp. 437-444
Closed Access | Times Cited: 72
Assessing Elementary Lesions in Gout by Ultrasound: Results of an OMERACT Patient-based Agreement and Reliability Exercise
Lene Terslev, Marwin Gutiérrez, Robin Christensen, et al.
The Journal of Rheumatology (2015) Vol. 42, Iss. 11, pp. 2149-2154
Open Access | Times Cited: 71
Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users
Chengsheng Ju, Rachel Wing Chuen Lai, Ka Hou Christien Li, et al.
Lara D. Veeken (2019) Vol. 59, Iss. 9, pp. 2340-2349
Open Access | Times Cited: 71
Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk
Claudio Borghi, Andrzej Tykarski, Krystyna Widecka, et al.
Cardiology Journal (2018) Vol. 25, Iss. 5, pp. 545-563
Open Access | Times Cited: 70
2020 recommendations from the French Society of Rheumatology for the management of gout: Urate-lowering therapy
Tristan Pascart, Augustin Latourte, René‐Marc Flipo, et al.
Joint Bone Spine (2020) Vol. 87, Iss. 5, pp. 395-404
Open Access | Times Cited: 68
Management of Hyperuricemia in Patients with Chronic Kidney Disease: a Focus on Renal Protection
Jan T. Kielstein, Roberto Pontremoli, Michel Burnier
Current Hypertension Reports (2020) Vol. 22, Iss. 12
Open Access | Times Cited: 67
Page 1 - Next Page

Scroll to top